Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer
A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer
Status: Enrolling
Updated:  9/20/2005
Department Of Veterans Affairs NJ Health Care System
mi
from
East Orange, NJ
A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer
A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer
Status: Enrolling
Updated: 9/20/2005
Department Of Veterans Affairs NJ Health Care System
mi
from
East Orange, NJ
Click here to add this to my saved trials
A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer
A Phase II Trial of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Hormone Resistant Prostate Cancer (HRPC)
Status: Enrolling
Updated:  9/20/2005
Department Of Veterans Affairs NJ Health Care System
mi
from
East Orange, NJ
A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer
A Phase II Trial of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Hormone Resistant Prostate Cancer (HRPC)
Status: Enrolling
Updated: 9/20/2005
Department Of Veterans Affairs NJ Health Care System
mi
from
East Orange, NJ
Click here to add this to my saved trials
Shared Decision-Making for Colorectal Cancer Screening
Shared Decision-Making for Colorectal Cancer Screening
Status: Enrolling
Updated:  11/9/2005
Boston Med Center
mi
from
Boston, MA
Shared Decision-Making for Colorectal Cancer Screening
Shared Decision-Making for Colorectal Cancer Screening
Status: Enrolling
Updated: 11/9/2005
Boston Med Center
mi
from
Boston, MA
Click here to add this to my saved trials
Shared Decision-Making for Colorectal Cancer Screening
Shared Decision-Making for Colorectal Cancer Screening
Status: Enrolling
Updated:  11/9/2005
South Boston Community Health Center
mi
from
Boston, MA
Shared Decision-Making for Colorectal Cancer Screening
Shared Decision-Making for Colorectal Cancer Screening
Status: Enrolling
Updated: 11/9/2005
South Boston Community Health Center
mi
from
Boston, MA
Click here to add this to my saved trials
Once Weekly Radiation for Lung Cancer With Chemotherapy
Combination of Weekly Radiation and Docetaxel for Locally Advanced Non Small Cell Lung Cancer: A Feasibility Study
Status: Enrolling
Updated:  11/18/2005
Cancer Center and Mobile Infirmary Hospital
mi
from
Mobile, AL
Once Weekly Radiation for Lung Cancer With Chemotherapy
Combination of Weekly Radiation and Docetaxel for Locally Advanced Non Small Cell Lung Cancer: A Feasibility Study
Status: Enrolling
Updated: 11/18/2005
Cancer Center and Mobile Infirmary Hospital
mi
from
Mobile, AL
Click here to add this to my saved trials
Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy
Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study
Status: Enrolling
Updated:  11/21/2005
Providence Hospital,
mi
from
Mobile, AL
Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy
Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study
Status: Enrolling
Updated: 11/21/2005
Providence Hospital,
mi
from
Mobile, AL
Click here to add this to my saved trials
Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy
Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study
Status: Enrolling
Updated:  11/21/2005
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy
Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study
Status: Enrolling
Updated: 11/21/2005
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Defining the Interaction of Docetaxel and Lonafarnib in Patients With Advanced Malignancies
Status: Enrolling
Updated:  2/6/2006
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Defining the Interaction of Docetaxel and Lonafarnib in Patients With Advanced Malignancies
Status: Enrolling
Updated: 2/6/2006
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Effect of a Nutritional Supplement on H&N Cancer Patients
The Effect of an Enhanced Nutritional Supplement on Head and Neck Cancer Patients
Status: Enrolling
Updated:  2/23/2006
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
Effect of a Nutritional Supplement on H&N Cancer Patients
The Effect of an Enhanced Nutritional Supplement on Head and Neck Cancer Patients
Status: Enrolling
Updated: 2/23/2006
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
Click here to add this to my saved trials
Effect of a Nutritional Supplement on H&N Cancer Patients
The Effect of an Enhanced Nutritional Supplement on Head and Neck Cancer Patients
Status: Enrolling
Updated:  2/23/2006
Hines VA Hospital
mi
from
Hines, IL
Effect of a Nutritional Supplement on H&N Cancer Patients
The Effect of an Enhanced Nutritional Supplement on Head and Neck Cancer Patients
Status: Enrolling
Updated: 2/23/2006
Hines VA Hospital
mi
from
Hines, IL
Click here to add this to my saved trials
Effect of Samarium on the Relief of Pain Due to Vertebral Metastases
Phase I/II Study of the Use of Vertebral Intracavitary Cement and Samarium (VICS) for Painful Vertebral Metastases
Status: Enrolling
Updated:  9/8/2006
New York Methodist Hospital
mi
from
Brooklyn, NY
Effect of Samarium on the Relief of Pain Due to Vertebral Metastases
Phase I/II Study of the Use of Vertebral Intracavitary Cement and Samarium (VICS) for Painful Vertebral Metastases
Status: Enrolling
Updated: 9/8/2006
New York Methodist Hospital
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Feasibility of Radiofrequency Ablation in the Management of Papillary Thyroid Cancer Under Ultra-Sound Guidance.
Feasibility of Radio-Frequency Ablation in the Management of Papillary Thyroid Cancer Under Ultra-Sound Guidance
Status: Enrolling
Updated:  9/26/2006
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Feasibility of Radiofrequency Ablation in the Management of Papillary Thyroid Cancer Under Ultra-Sound Guidance.
Feasibility of Radio-Frequency Ablation in the Management of Papillary Thyroid Cancer Under Ultra-Sound Guidance
Status: Enrolling
Updated: 9/26/2006
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Effects of Case Management in a Medicaid Managed Care Plan
The Effects of Case Management in a Medicaid Managed Care Plan
Status: Enrolling
Updated:  10/10/2006
Metropolitan Jewish Health System
mi
from
Brooklyn, NY
The Effects of Case Management in a Medicaid Managed Care Plan
The Effects of Case Management in a Medicaid Managed Care Plan
Status: Enrolling
Updated: 10/10/2006
Metropolitan Jewish Health System
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Genetic Counseling in African American Women
Genetic Counseling for Breast Cancer Susceptibility in African American Women
Status: Enrolling
Updated:  3/21/2007
Univ of Pennsylvania
mi
from
Philadelphia, PA
Genetic Counseling in African American Women
Genetic Counseling for Breast Cancer Susceptibility in African American Women
Status: Enrolling
Updated: 3/21/2007
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Lived Experiences of Adolescents in the Treatment Process of Cancer and the Impact on Occupations
Lived Experiences of Adolescents in the Treatment Process of Cancer and the Impact of Occupations
Status: Enrolling
Updated:  4/3/2007
Hackensack University Medical Center
mi
from
Hackensack, NJ
Lived Experiences of Adolescents in the Treatment Process of Cancer and the Impact on Occupations
Lived Experiences of Adolescents in the Treatment Process of Cancer and the Impact of Occupations
Status: Enrolling
Updated: 4/3/2007
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
TRIAD Burden of Illness Mucositis Study
Risk and Outcomes of Mucositis in Subjects Being Treated for Breast, Colorectal, Head and Neck, Non-Small Cell Lung Cancers or Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/19/2007
Univeristy Of Wisconsin
mi
from
Madison, WI
TRIAD Burden of Illness Mucositis Study
Risk and Outcomes of Mucositis in Subjects Being Treated for Breast, Colorectal, Head and Neck, Non-Small Cell Lung Cancers or Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/19/2007
Univeristy Of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
A Phase II Study of MS-275, in Combination With GM-CSF Treating Relapsed and Refractory Myeloid Malignancies
A Phase II Study of an Oral Histone Deacetylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies
Status: Enrolling
Updated:  4/25/2007
Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
A Phase II Study of MS-275, in Combination With GM-CSF Treating Relapsed and Refractory Myeloid Malignancies
A Phase II Study of an Oral Histone Deacetylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies
Status: Enrolling
Updated: 4/25/2007
Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Seton Medical Mangement Dba Oncology Center at Providence Hospital
mi
from
Mobile, AL
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Seton Medical Mangement Dba Oncology Center at Providence Hospital
mi
from
Mobile, AL
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Rocky Mountain Gynecology & Oncology
mi
from
Englewood, CO
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Rocky Mountain Gynecology & Oncology
mi
from
Englewood, CO
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Florida Gynecologic Oncology
mi
from
Fort Myers, FL
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Florida Gynecologic Oncology
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Jupiter Medical Center-Gynecology Oncology and Gynecology
mi
from
Jupiter, FL
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Jupiter Medical Center-Gynecology Oncology and Gynecology
mi
from
Jupiter, FL
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Florida Hospital/Gyn/Onc Department
mi
from
Orlando, FL
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Florida Hospital/Gyn/Onc Department
mi
from
Orlando, FL
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Augusta Oncology Associates
mi
from
Augusta, GA
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Augusta Oncology Associates
mi
from
Augusta, GA
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Med College of Georgia
mi
from
Augusta, GA
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Med College of Georgia
mi
from
Augusta, GA
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
University of Illinois/Department of Gynecology Oncology
mi
from
Chicago, IL
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
University of Illinois/Department of Gynecology Oncology
mi
from
Chicago, IL
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Evanston North Health Care
mi
from
Evanston, IL
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Evanston North Health Care
mi
from
Evanston, IL
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Hematology-Onc. Assoc. of The Quad Cities
mi
from
Bettendorf, IA
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Hematology-Onc. Assoc. of The Quad Cities
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
University of Iowa
mi
from
Iowa City, IA
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Hematology & Oncology Specialists/Dept. of OB/GYN
mi
from
New Orleans, LA
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Hematology & Oncology Specialists/Dept. of OB/GYN
mi
from
New Orleans, LA
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Franklin Square Hospital Center/MedStar Health-Section of Hematology/Oncology
mi
from
Baltimore, MD
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Franklin Square Hospital Center/MedStar Health-Section of Hematology/Oncology
mi
from
Baltimore, MD
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Saint Luke's Hospital of Kansas City/The Cancer Institute
mi
from
Kansas City, MO
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Saint Luke's Hospital of Kansas City/The Cancer Institute
mi
from
Kansas City, MO
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Cancer Center at Hackensack
mi
from
Hackensack, NJ
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Cancer Center at Hackensack
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Columbia University College of Physicians and Surg
mi
from
New York, NY
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Columbia University College of Physicians and Surg
mi
from
New York, NY
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Hope: A Woman's Cancer Center
mi
from
Asheville, NC
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Hope: A Woman's Cancer Center
mi
from
Asheville, NC
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
University of North Carolina/ Division of Gyn Oncology
mi
from
Chapel Hill, NC
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
University of North Carolina/ Division of Gyn Oncology
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Carolinas Medical Center/Gyn Oncology Department
mi
from
Charlotte, NC
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Carolinas Medical Center/Gyn Oncology Department
mi
from
Charlotte, NC
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Duke University/Division of Gynecologic Oncology
mi
from
Durham, NC
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Duke University/Division of Gynecologic Oncology
mi
from
Durham, NC
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Moses H. Cone Health System/ Regional Cancer Center
mi
from
Greensboro, NC
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Moses H. Cone Health System/ Regional Cancer Center
mi
from
Greensboro, NC
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Forsyth Regional Cancer Center
mi
from
Winston-Salem, NC
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Forsyth Regional Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Gynecologic Oncology and Surgery
mi
from
Oklahoma City, OK
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Gynecologic Oncology and Surgery
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
PA Hematology/Oncology Associates
mi
from
Philadelphia, PA
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
PA Hematology/Oncology Associates
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
MUSC-Div of Gyn/Oncology
mi
from
Charleston, SC
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
MUSC-Div of Gyn/Oncology
mi
from
Charleston, SC
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
The West Cancer Clinic
mi
from
Memphis, TN
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
The West Cancer Clinic
mi
from
Memphis, TN
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Southwest Regional Cancer Center
mi
from
Austin, TX
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Southwest Regional Cancer Center
mi
from
Austin, TX
Click here to add this to my saved trials
A Prospective Study of a New Immunochemical Fecal Occult Blood Test in U.S. Veteran Patients Undergoing Colonoscopy
A Prospective Study of a New Immunochemical Fecal Occult Blood Test in U.S. Veteran Patients Undergoing Colonoscopy
Status: Enrolling
Updated:  9/20/2007
Veteran Affairs Medical Center San Diego
mi
from
San Diego, CA
A Prospective Study of a New Immunochemical Fecal Occult Blood Test in U.S. Veteran Patients Undergoing Colonoscopy
A Prospective Study of a New Immunochemical Fecal Occult Blood Test in U.S. Veteran Patients Undergoing Colonoscopy
Status: Enrolling
Updated: 9/20/2007
Veteran Affairs Medical Center San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Impact of a Mailed Educational Reminder on Fecal Occult Blood Testing (FOBT): A Randomized Controlled Trial
Impact of a Mailed Educational Reminder on Fecal Occult Blood Testing (FOBT): A Randomized Controlled Trial
Status: Enrolling
Updated:  9/20/2007
Veteran Affairs Medical Center San Diego
mi
from
San Diego, CA
Impact of a Mailed Educational Reminder on Fecal Occult Blood Testing (FOBT): A Randomized Controlled Trial
Impact of a Mailed Educational Reminder on Fecal Occult Blood Testing (FOBT): A Randomized Controlled Trial
Status: Enrolling
Updated: 9/20/2007
Veteran Affairs Medical Center San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study
Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymp Node Positive Breast Cancer: A Pilot Study
Status: Enrolling
Updated:  10/23/2007
Premiere Oncology
mi
from
Santa Monica, CA
Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study
Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymp Node Positive Breast Cancer: A Pilot Study
Status: Enrolling
Updated: 10/23/2007
Premiere Oncology
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer
Phase I/II Trial of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Androgen-Independent Prostate Cancer
Status: Enrolling
Updated:  12/17/2007
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer
Phase I/II Trial of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Androgen-Independent Prostate Cancer
Status: Enrolling
Updated: 12/17/2007
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials